STOCK TITAN

Cormedix Stock Price, News & Analysis

CRMD Nasdaq

Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.

Cormedix Inc (CRMD) is a clinical-stage biopharmaceutical company pioneering novel therapies for life-threatening infectious and inflammatory conditions. This news hub provides investors and healthcare stakeholders with essential updates on DefenCath developments, regulatory milestones, and therapeutic pipeline progress.

Access timely announcements including FDA correspondence, clinical trial data, and commercialization strategies for CRMD's catheter lock solutions. Our curated collection features earnings reports, partnership disclosures, and scientific presentations relevant to infection prevention in critical care settings.

Key updates cover therapeutic candidate advancements, intellectual property developments, and market expansion initiatives. Monitor progress in addressing bloodstream infections through CRMD's specialized antimicrobial formulations designed for high-risk patient populations.

Bookmark this page for structured access to verified corporate communications and analysis of how CRMD navigates the complex biopharmaceutical regulatory landscape. Stay informed on developments impacting both patient care standards and long-term therapeutic innovation.

Rhea-AI Summary
CorMedix Inc. (CRMD) reported strong Q1 2025 financial results with net revenue of $39.1 million and net income of $20.6 million ($0.32 per share), compared to a net loss in Q1 2024. The company achieved adjusted EBITDA of $23.6 million and positive cash flow from operations of $19.7 million. DefenCath sales drove performance, particularly in outpatient dialysis. The inpatient sales team is now fully operational, with institutional shipments doubling over three months. CorMedix commenced a Phase 3 study for reducing CLABSIs in TPN patients. The company expects to hit the high end of its H1 2025 sales guidance ($62-70 million) and reported cash and short-term investments of $77.5 million, sufficient for at least 12 months of operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.59%
Tags
-
Rhea-AI Summary

CorMedix (Nasdaq: CRMD), a biopharmaceutical company developing therapeutic products for life-threatening diseases, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, before market opening.

The company will host a corporate update conference call at 8:30am Eastern Time on the same day. Interested parties can join through:

  • Domestic call-in: 1-844-676-2922
  • International call-in: 1-412-634-6840
  • Conference ID: 10198548
  • Webcast available via provided link
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
conferences earnings
-
Rhea-AI Summary

CorMedix (NASDAQ: CRMD) reports strong preliminary Q1 2025 results with unaudited net revenue of $39.0 million and expected adjusted EBITDA exceeding $22.5 million. The company's cash position stands at $77.5 million as of March 31, 2025.

Due to larger than anticipated orders in late March and improved visibility into customer inventory levels, CorMedix has raised its H1 2025 net sales guidance to $62-70 million. While Q2 2025 sales are expected to be lower than Q1 due to shipment timing, patient utilization is forecast to grow throughout 2025, with H2 shipments projected to exceed H1.

The company plans to begin patient enrollment for DefenCath's Phase 3 study in Total Parenteral Nutrition (TPN) patients in late April. If approved, DefenCath's peak annual sales potential in this indication is estimated at $150-200 million, with a total addressable market of $500-750 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.86%
Tags
Rhea-AI Summary

CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The event will be held virtually from April 7-10, 2025.

The company's management will engage in a Fireside Chat scheduled for Tuesday, April 8, 2025, at 2:15 p.m. EDT. This participation aligns with CorMedix's ongoing efforts to maintain investor relations and industry presence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
conferences
-
Rhea-AI Summary

CorMedix (NASDAQ: CRMD) reported strong financial results for Q4 and full year 2024, marking its first profitable commercial quarter. The company achieved Q4 net revenue of $31.2 million and full-year revenue of $43.5 million, primarily driven by DefenCath sales since its outpatient launch in July 2024.

Q4 highlights include net income of $13.5 million and adjusted EBITDA of $15.3 million. The company ended 2024 with $51.7 million in cash and short-term investments. CorMedix provided preliminary guidance for H1 2025 with expected net revenue of $50-60 million, including over $33 million in Q1.

Key developments include partnering with Syneos Health for inpatient sales team building and WSI for VA facilities marketing. The company is preparing to commence a Phase 3 study of DefenCath in Total Parenteral Nutrition patients in Q2 2025, with a pending FDA Orphan Drug Status application.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.85%
Tags
-
Rhea-AI Summary

CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has scheduled its Q4 and Full Year 2024 financial results announcement. The company will release its financial performance report before market opens on March 25, 2025, followed by a corporate update conference call at 8:30am Eastern Time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
conferences earnings
Rhea-AI Summary

CorMedix (Nasdaq: CRMD), a biopharmaceutical company, has announced a collaboration with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities.

This partnership aims to enhance access to critical therapies for approximately 40,000 veterans living with end-stage renal disease (ESRD) and other beneficiaries of federal programs. WSI PBG will leverage its expertise in navigating VA and federal facilities, including access, procurement processes, and regulations, to meet the unique needs of these healthcare systems.

CorMedix and WSI PBG are committed to improving health outcomes by providing increased access to DefenCath for patients at VA and other federal facilities. Joe Todisco, CEO of CorMedix, expressed excitement about the collaboration, citing WSI PBG's deep understanding of the federal healthcare landscape as a key factor in enhancing access to DefenCath and ensuring equitable care for veterans and other federal healthcare beneficiaries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
-
Rhea-AI Summary

CorMedix (NASDAQ: CRMD) reports strong preliminary Q4 2024 results with unaudited net revenue of approximately $31 million and full-year 2024 revenue of $43 million. Q4 adjusted EBITDA is expected to exceed $12 million, achieving the company's breakeven target by year-end 2024.

The company has secured over $25 million in open purchase orders for Q1 2025 delivery and is actively shipping DefenCath to three midsized dialysis operators. CorMedix plans to expand into the inpatient hospital segment in Q1 2025 through a partnership with Syneos Health for dedicated sales team deployment. The company projects FY 2025 operating expenses of $72-78 million, with increased R&D spending for clinical initiatives.

As of December 31, 2024, CorMedix maintains a strong financial position with approximately $52 million in cash and short-term investments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.89%
Tags
-
Rhea-AI Summary

CorMedix Inc. (CRMD) has announced its upcoming addition to the Nasdaq Biotechnology Index (NBI), effective before market open on Monday, December 23, 2024. The NBI is a modified market capitalization weighted index tracking NASDAQ-listed biotechnology and pharmaceutical companies. Inclusion in the index is based on specific eligibility criteria, including minimum market capitalization and average daily trading volume requirements. The index undergoes annual reconstitution in December.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.24%
Tags
none
Rhea-AI Summary

CorMedix welcomes significant CMS policy updates that will enhance hemodialysis patients' access to innovative therapies. Starting January 2025, CMMI's Kidney Care Choices model will exclude TDAPA payments from financial calculations, facilitating access to new drugs including DefenCath®. This change affects over 30% of ESRD patients in the US currently enrolled in KCC programs, removing financial barriers to innovative drug utilization and ensuring patient care choices aren't by cost considerations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none

FAQ

What is the current stock price of Cormedix (CRMD)?

The current stock price of Cormedix (CRMD) is $11.66 as of May 9, 2025.

What is the market cap of Cormedix (CRMD)?

The market cap of Cormedix (CRMD) is approximately 636.1M.
Cormedix

Nasdaq:CRMD

CRMD Rankings

CRMD Stock Data

636.06M
63.48M
1.25%
39.99%
12.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
BERKELEY HEIGHTS